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TPIL1
ANALYSIS OF DIRECT, INDIRECT, AND
TOTAL COSTS OF ASTHMA FROM PATIENT 
SURVEY DATA
Johnson KA, Ernst RL, Ogostalick AE
University of Southern California, Los Angeles, CA, USA
OBJECTIVE: This study estimated the direct, indirect, and
total costs of asthma and evaluated the impact of symp-
tom severity, disease control, and the National Asthma
Education and Prevention Program treatment guidelines
on cost of asthma care using patient survey data.
METHODS: Data were obtained from a 1993 US house-
hold survey to determine the costs of asthma (N  698).
Costs were developed by assigning unit costs to reported
medical utilization and unpaid resource usage and were
reported in 1994 US dollars. A multivariate regression
model was developed to determine factors associated with
higher asthma costs.
RESULTS: The average annual total cost of asthma care
was US$966 per person, ranging from US$47 (controlled
symptoms) to US$7030 (uncontrolled symptoms). Costs
for uncontrolled patients were due mainly to costs of
hospitalization and indirect costs of missed days from
work. Based on the reported incidence of asthma in the
United States, the cost of asthma care is estimated at
US$9.6 billion. Significant predictors of higher direct, indi-
rect, and total costs of asthma include symptom severity (p
 0.001) and following pharmacotherapy guidelines (p 
0.01). Younger age is associated with higher costs in the
indirect and total cost models (p  0.01 and p  0.05).
Smoking is associated with higher indirect costs (p 
0.05). Lower total and direct costs are associated with pa-
tients who self-pay for healthcare (p  0.05). Lower indi-
rect costs are associated with patients who report their
asthma is controlled (p  0.05).
CONCLUSION: Symptom severity is associated with
higher asthma care costs. Our findings suggest that either
people not meeting guidelines also have zero medical ex-
penses or adherence to the treatment guidelines actually
increases costs. A prospective study is necessary to deter-
mine the impact of guidelines.
TPIL2
THE COST OF TREATING PARKINSON’S 
DISEASE (PD) IN THE CALIFORNIA MEDICAID 
(MEDI-CAL) PROGRAM
McCombs JS, Nichol MB, Lyu RR, Shi L
Department of Pharmaceutical Economics & Policy, University 
of Southern California, Los Angeles, CA, USA
OBJECTIVE: A critical factor used by healthcare organi-
zations in evaluating new medications is baseline data on
current costs of treating the disease in question. This
study investigated the healthcare use and cost patterns
for PD patients in the Medi-Cal program.
METHODS: The data for the analysis were derived from
the paid claims data of Medi-Cal program from January
1987 to July 1996. Up to 4 years of episodic anti-PD drug
use patterns and associated direct healthcare costs were
abstracted for each patient. Descriptive statistics and mul-
tivariate OLS models were employed in the study.
RESULTS: Although a significant proportion of PD pa-
tients did not use any anti-PD regimen during the first
year (23.4% of institutionalized patients, 17.5% of com-
munity-based patients), anti-PD drug use was negatively
correlated with total first-year healthcare costs (yet not
significant) in both groups. Significant association was
found between prior hospitalization and healthcare costs
(P  0.0001). No statistically significant differences were
found across alternative anti-PD medications when used
as initial therapy for both community-based and institu-
tionalized patients. Healthcare expenditures of commu-
nity-based patients increased from approximately $11,000
per patient for the first treatment year to over $27,000 per
patient-year by the end of 4 years. Annual costs for insti-
tutionalized patients in the first year exceeded $85,000
per patient-year and decreased slightly over 4 years.
Compliance rate in community-based PD patients was
significantly lower than that of institutionalized patients
(25% versus 57%, p  0.001).
CONCLUSIONS: Anti-PD drug therapy might have po-
tential cost saving effect on first-year healthcare services.
Prior use of hospital service was a significant predictor of
overall direct healthcare costs of PD patients in the Medi-
Cal program.
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THE MEDICAL COST OF OSTEOARTHRITIS
AND RHEUMATOID ARTHRITIS: METHODS
AND EVIDENCE
Lee DW2, Meyer J1, Clouse J1
1Ingenix, Eden Prairie, MN, USA; 2GD Searle, Skokie, IL, USA
OBJECTIVE: To evaluate the impact of controlling and
not controlling for comorbid conditions on the estimated
cost of osteoarthritis (OA) and rheumatoid arthritis (RA)
in a managed care setting.
METHODS: Medical claims data from 1996 were ob-
tained for inpatient, outpatient and pharmacy services
for members in five United Health–affiliated health plans
(enrollment: 884,000). Total costs for arthritis patients
( 1 claims with an arthritis diagnosis and  30 days of
continuous enrollment) were compared to costs among
an equal number of comparison members who were se-
lected at random after stratification by health plan, gen-
der, age category, and Medicare status. Multivariate re-
gression analysis was used to compare the natural log of
costs between the two groups under three alternative
